U.S. Markets open in 5 mins.

GlaxoSmithKline plc (GSK)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
44.07-0.22 (-0.50%)
At close: 4:02PM EDT

44.01 -0.05 (-0.11%)
Pre-Market: 9:24AM EDT

People also watch
AZNNVSSNYLLYBMY
Full screen
Previous Close44.29
Open44.24
Bid44.01 x 1000
Ask44.04 x 1900
Day's Range44.05 - 44.44
52 Week Range37.20 - 45.58
Volume8,940
Avg. Volume3,004,204
Market Cap107.04B
Beta1.06
PE Ratio (TTM)50.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.95 (4.41%)
Ex-Dividend Date2017-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • Forbes48 minutes ago

    The Forgotten $35 Billion U.S. Health Care Problem

    Each year, more than 23,000 people die in the U.S. as a result of bacterial infections that are resistant to antibiotics – the equivalent of a Boeing 747 crashing each week. Worse, there are at least 2 million people each year who acquire serious infections by bacteria resistant to antibiotics.

  • GSK's new CEO aims to divest sports nutrition brand: sources
    Reuters5 days ago

    GSK's new CEO aims to divest sports nutrition brand: sources

    GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday. GSK bought the business, which makes protein bars, drinks and powders, for 162 million pounds ($205 million) in 2010 under previous CEO Andrew Witty. The original acquisition was seen as complementing GSK's Lucozade sports drinks.

  • Glaxo's (GSK) Shingles Candidate Phase III Data Positive
    Zacks5 days ago

    Glaxo's (GSK) Shingles Candidate Phase III Data Positive

    GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.